Omaha, Neb.-based Transgenomic has granted a license to the University of Melbourne to use its Multiplexed ICE COLD-PCRtechnology for research and clinical applications.
MX-ICP, a high sensitivity DNA amplification technology, enables the detection of mutations in multiple genes from either tumors or any liquid sample, such as blood or urine.
The university will receive a license in Australia to Transgenomic’s new EGFR liquid biopsy cancer assays under the agreement.
The four tests detect specific actionable mutations associated with sensitivity or resistance to targeted drugs used for colorectal and non-small cell lung cancer in many sample types, although mainly in blood and plasma. — Michael Cipriano